Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib plus paclitaxel/carboplatin vs paclitaxel/carboplatin in platinum-sensitive serous ovarian cancer
jRCT2080221047Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of olaparib in Serous Papillary Cystadenocarcinoma (2 arms), sponsored by AstraZeneca. Started Mar 2010; status: completed.
02
Drugs
olaparib
03
Conditions
Serous Papillary Cystadenocarcinoma
Beyond the preview
Go deeper on jRCT2080221047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221047.